Cogentix Medical (CGNT) Downgraded by Zacks Investment Research
Zacks Investment Research cut shares of Cogentix Medical (NASDAQ:CGNT) from a buy rating to a hold rating in a research report report published on Wednesday morning.
According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “
A number of other analysts have also commented on CGNT. JMP Securities initiated coverage on shares of Cogentix Medical in a report on Friday, October 6th. They set an outperform rating and a $5.00 target price for the company. Roth Capital initiated coverage on shares of Cogentix Medical in a report on Wednesday, November 8th. They set a buy rating and a $4.00 target price for the company. TheStreet raised shares of Cogentix Medical from a d+ rating to a c rating in a report on Thursday, November 9th. Finally, Aegis initiated coverage on shares of Cogentix Medical in a report on Friday, December 1st. They set a buy rating and a $4.75 target price for the company. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $4.06.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of Cogentix Medical by 0.4% during the second quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock worth $129,000 after purchasing an additional 326 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Cogentix Medical during the third quarter worth $152,000. Renaissance Technologies LLC boosted its position in shares of Cogentix Medical by 2.3% during the first quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock worth $1,013,000 after purchasing an additional 12,459 shares in the last quarter. Finally, Broadfin Capital LLC boosted its position in shares of Cogentix Medical by 45.2% during the second quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock worth $1,905,000 after purchasing an additional 340,771 shares in the last quarter. 13.31% of the stock is currently owned by institutional investors.
Cogentix Medical Company Profile
Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related stocks with our FREE daily email newsletter.